BiotechTube

PF-02545920 + Placebo + PF-02545920 + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Huntington's Disease

Conditions

Huntington's Disease

Trial Timeline

Sep 1, 2013 → Jan 1, 2015

NCT ID
NCT01806896

About PF-02545920 + Placebo + PF-02545920 + Placebo

PF-02545920 + Placebo + PF-02545920 + Placebo is a phase 2 stage product being developed by Pfizer for Huntington's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01806896. Target conditions include Huntington's Disease.

What happened to similar drugs?

1 of 2 similar drugs in Huntington's Disease were approved

Approved (1) Terminated (1) Active (0)
✅TetrabenazineLundbeckApproved
❌SAGE-718Supernus PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01806896Phase 2Completed

Competing Products

15 competing products in Huntington's Disease

See all competitors
ProductCompanyStageHype Score
AFQ056 + PlaceboNovartisPhase 2
27
RO7234292 (RG6042)RochePhase 2
35
RG6496 + PlaceboRochePhase 1
36
PF-02545920 + PF-02545920PfizerPhase 2
35
20 mg BID of PF-02545920PfizerPhase 2
27
ALN-HTT02 + PlaceboAlnylam PharmaceuticalsPhase 1
33
TetrabenazineLundbeckApproved
36
BN82451B + PlaceboIpsenPhase 2
24
ISIS 443139 10 mg + ISIS 443139 30 mg + ISIS 443139 60 mg + ISIS 443139 90 mg + ISIS 443139 120 mgIonis PharmaceuticalsPhase 1/2
29
WVE-120102 + PlaceboWaVe Life SciencesPhase 1/2
18
WVE-120101 + PlaceboWaVe Life SciencesPhase 1/2
18
SAGE-718Supernus PharmaceuticalsPhase 3
26
SAGE-718 + PlaceboSupernus PharmaceuticalsPhase 2
29
OMS643762 + PlaceboOmeros CorporationPhase 2
21
VX15/2503 + PlaceboVaccinexPhase 2
25